Influence of Reboxetine on Salivary MHPG Concentration and Cognitive Symptoms Among Patients with Alcohol-Related Korsakoff's Syndrome

Reuster, Thomas; Buechler, J; Winiecki, P; Oehler, Jochen

doi:10.1038/sj.npp.1300118

Cited by 20 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Search terms including <name of marker> in articles on WKS led to search results composed of a much reduced set of items, namely brain tissue cell counts of CD68 positive cells in an animal model and high cerebrospinal fluid lactate levels in six children suffering from WE . As biomarkers for delirium were being sought, findings of low MHPG concentrations in patients with long‐standing Korsakoff's and descriptions of cerebrospinal fluid BDNF levels in alcohol‐induced dementia were not taken into account .…”

Section: Resultsmentioning

confidence: 99%

Biomarkers of delirium as a clue to diagnosis and pathogenesis of Wernicke−Korsakoff syndrome

Wijnia¹,

Oudman

2013

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarkers of delirium as a clue to diagnosis and pathogenesis of Wernicke−Korsakoff syndrome

Wijnia¹,

Oudman

2013

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…This finding resembled the physiological conditions, when ã power is most prominent during the presence of hippocampal è activity and thought to be associated with cognitive functions (11,48). Given the correlation between the septo-hippocampal oscillatory activity and cognitive processes, the action of reboxetine on this circuit could explain its ability to enhance temporal information processing in healthy humans (103), its lack of disrupting cognitive function (59,122,114), and its capacity to improve cognitive disturbances associated with depression (35,36,67) or other disorders (105). In addition, selective enhancement of NE neurotransmission could be the central mechanism contributing to the reboxetine-induced improvement of social functioning in depression (13,30,31).…”

Section: Norepinephrine Cognitive Function and Reboxetinementioning

confidence: 99%

The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile

et al. 2004

View full text Add to dashboard Cite

Reboxetine is the first commercially available norepinephrine reuptake inhibitor developed specifically as a first line therapy for major depressive disorder. In vitro and in vivo pharmacological studies indicated that reboxetine methanesulphonate has high affinity and selectivity for the human norepinephrine transporter over the serotonin and dopamine transporters. Pharmacological specificity is further demonstrated by the absence of affinity for 45 transmitter receptors and CNS targets. Pharmacokinetic studies demonstrated that reboxetine is suitable for twice daily administration (8-10 mg/day) and that it exhibits minimal drug-drug interactions. The starting dose of reboxetine should be reduced in the elderly, in patients with renal or hepatic impairment, or in patients receiving potent CYP3A inhibitors. A total of 20 phase II/III clinical studies comprising placebo-controlled, active comparator-controlled and open-label uncontrolled studies in both short-term and long-term treatment of major depression have been conducted. In the treatment of major depression, reboxetine was superior to placebo in 5 of 12 short- or long-term placebo-controlled studies and was comparable in efficacy to active comparators in 3 out of 3 active-controlled studies. Unlike conventional tricyclic antidepressants (TCAs), reboxetine had only minimal sedative and cardiovascular liabilities, probably due to increased pharmacological specificity of reboxetine as compared with TCAs. Unlike serotonin reuptake inhibitors, this selective and specific norepinephrine reuptake inhibitor demonstrated a distinct side-effect profile with diminishing sexual dysfunction and GI side effects. The availability of this agent has afforded patients suffering from major depressive disorder a new class of agents to combat the debilitating consequence of this psychiatric disease. The demonstrated pharmacological specificity of this compound has provided the psychopharmacology community with a tool to elucidate the role of norepinephrine in brain functions. Testing this agent in different animal models has enabled the exploration of the role of modulation of norepinephrine tone in the therapy of CNS disorders beyond depression.

show abstract

“…However, as this study was based on a single patient displaying frequent violent behavioural outbursts, this finding may not be generalizable to other individuals with ARBD. There was no evidence within this review to suggest that Desglycinamide Arginine Vasopressin (DGAVP; JennekinsSchinkel et al, 1985); Physostigmin (O'Donnell et al, 1986); Reboxetine (Reuster et al, 2003) and Rivastgmine (Luykx et al, 2008) should be used to treat patients with ARBD.…”

Section: Other Drug Treatmentsmentioning

confidence: 90%

Interventions for alcohol-related brain damage (ARBD): Do specific approaches restrict the evolution of comprehensive patient care?

Horton

Duffy

Martin

2014

Drugs: Education, Prevention and Policy

View full text Add to dashboard Cite

show abstract

Influence of Reboxetine on Salivary MHPG Concentration and Cognitive Symptoms Among Patients with Alcohol-Related Korsakoff's Syndrome

Cited by 20 publications

References 17 publications

Biomarkers of delirium as a clue to diagnosis and pathogenesis of Wernicke−Korsakoff syndrome

Biomarkers of delirium as a clue to diagnosis and pathogenesis of Wernicke−Korsakoff syndrome

The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile

Interventions for alcohol-related brain damage (ARBD): Do specific approaches restrict the evolution of comprehensive patient care?

Contact Info

Product

Resources

About